NCT01012414终止3 期
The Effect of Vitamin D Supplementation on Markers of Inflammation in High-Risk Cardiovascular Patients With Low Levels of Serum 25-Hydroxyvitamin D
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Change in High Sensitivity-C Reactive Protein (Serum)
研究概览
简要总结
The purpose of this study is to determine if vitamin D supplementation changes the results of certain tests associated with inflammation in the body using an oral, synthetic form of vitamin D called paricalcitol.
详细描述
Vitamin D deficiency is common and has been associated with an increased risk of heart disease. In patients with the combination of kidney disease and heart disease, inflammation is thought to contribute to a high rate of cardiac events. Less is known about the effects of vitamin D supplementation on certain tests associated with inflammation in the body.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and non-pregnant, non-lactating women greater than 18 years of age
- •Able to given informed consent and complete scheduled visits
- •History of established coronary artery disease (CAD)as defined by coronary stenosis in one or more vessels greater than or equal to 70% by coronary angiography or CT angiogram OR abnormal stress test (at least medium-sized, moderate reversible defect) OR a presence of a CAD risk equivalent as defined by the National Cholesterol Education Panel (NCEP)III as: Framingham risk score ≥ 20%, diabetes, or peripheral arterial disease(4)
- •High Sensitivity C-reactive Protein (hs-CRP) ≥ 2.0 mg/L
- •History of stage 3 or 4 chronic Kidney disease (CKD) defined as an glomerular filtration rate (eGRF) by the Modification of Diet in Renal Disease (MDRD) formula of 15-60 mL/min/1.73 m2
- •Low level of serum 25-hydroxyvitamin D (<30ng/mL)
- •Evidence of secondary hyperparathyroidism defined as intact parathyroid hormone (iPTH) level > 70 pg/mL
- •Stable dose of statin and/or other lipid lowering therapy (ie: ezetimibe, fibrates, bile acid sequestrants nicotinic acid, fish oil) for 12 weeks prior to enrollment without known plans for change to current therapy during the study period
排除标准
- •History of myocardial infarction, stroke, or cardiac surgery within 6 months of enrollment
- •History of carotid artery surgery
- •Planned cardiovascular surgery or procedure, with the exception of permanent pacemaker placement, in the next 18 months.
- •Use of vitamin D or calcium supplementation within the past 12 weeks with the exception of calcium containing phosphate binders and a daily multivitamin containing ≤ 400 IU of vitamin D
- •Hypercalcemia (as defined by the laboratory upper limit of normal ) or hyperphosphatemia (≥ 5.5 mg/dL)
- •Plan to initiate renal replacement therapy (dialysis) during the study
- •History of left ventricular systolic dysfunction with an ejection fraction <50% or history of New York Heart Association (NYHA)functional Class II-IV congestive heart failure
- •Uncontrolled blood pressure, defined as systolic blood pressure greater than 160 mmHg and diastolic blood pressure greater than 100 mm Hg at the screening visit
- •Uncontrolled diabetes, defined as hemoglobin A1C ≥ 10.0
- •History of any surgery within the past 3 months or known to be planned during the study period
- •History of malignancy within the past 5 years with the exception of non-melanoma (ie: squamous cell or basal cell) skin cancer
- •History of a known systemic or pulmonary inflammatory condition (including rheumatoid arthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease, pulmonary fibrosis, sarcoidosis, Wegener's granulomatosis, Goodpasture's disease)
- •History of renal or other organ transplant and/or immunosuppressed state (ie immunosuppressive therapy or condition such as HIV)
- •History of any other condition, that in the opinion of the investigators renders it unsafe for the subject to be enrolled
- •For woman able to become pregnant, unwillingness to use birth control
- •Participation in another clinical trial
研究组 & 干预措施
oral paricalcitol 2 mcg daily
Experimental
oral paricalcitol 2 mcg daily
干预措施: paricalcitol (Drug)
Placebo
Placebo Comparator
one oral placebo drug daily
干预措施: placebo (Drug)
结局指标
主要结局
Change in High Sensitivity-C Reactive Protein (Serum)
时间窗: 1 year
次要结局
- Change in Markers of Inflammation Including Interleukin (IL)-1, IL-6, Tumor Necrosis Factor Alpha, Matrix Metalloproteinase (MMP) -9 and Serum Amyloid A(1 year)
- Effect on Known Coronary Artery Disease Risk Factors Including Lipids and Blood Pressure.(1 year)
- Effect on Carotid Intima-media Thickening (CIMT)(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Vitamin D Supplementation and Immunity/Physical PerformanceVitamin D StatusNCT03132103Bangor University260
终止
不适用
Vitamin D Supplementation and Metabolism in Vitamin D Deficient ElderlyVitamin D DeficiencyMetabolic SyndromeNCT01145703Baltimore VA Medical Center39
Unknown
不适用
Vitamin D Supplements on Markers for Cardiovascular Disease and Diabetes: an Individual Participant Data Meta-analysisVitamin D DeficiencyVitamin; Excess Vitamin D (Nutritional)NCT02551835Amsterdam UMC, location VUmc2,945
已完成
不适用
Vitamin D After Myocardial Infarction (MI): the DAMI studyAcute myocardial infarctionMyocardial infarctionISRCTN32927244niversity of Dundee (UK)80
进行中（未招募）
不适用
Effects of Vitamin D Supplementation on SOD,IL-6 and Insulin Resistance in Type 2 Diabetes Mellitus (DM)Type2 Diabetes MellitusNCT05596383Trisakti University112